Aminaphtone in the control of Schamberg's disease
© de Godoy and Batigália. 2009
Received: 22 February 2009
Accepted: 11 June 2009
Published: 11 June 2009
The aim of this case report is to describe control of Schamberg's disease using aminaphtone. We report on the case of a 28-year-old patient who presented with multiple purpuric lesions of the lower extremities which had appeared spontaneously. A biopsy of the skin was performed that showed a perivascular T-cell lymphocytic infiltrate centered on the small superficial blood vessels of the skin and so a diagnosis of Schamberg's disease was reached. The patient was prescribed corticoids and the lesions disappeared however on suspension of the medication the lesions re-emerged within three to seven days. This treatment was unsuccessfully continued for more than one year. Thus another therapeutic option was attempted: 75 mg of aminaphtone was prescribed twice daily for one month and the purpuric lesions disappeared within about one week. One year after suspending the medication no relapse of the purpura was observed.
Since progressive pigmented purpuric dermatitis, also known as Schamberg's disease, was first described in 1901, several articles have appeared that have dealt largely with clinical and histologic features of the illness. The lesions may occur in any location but most often affect the lower extremities. The skin lesions are nonpalpable macules, which are typically asymptomatic, may persist for months to years; normally only the aesthetic appearance is of concern to patients .
Histologic examinations show a lymphocytic vasculitis involving the blood vessels of the upper dermis with endothelial swelling and extravasated red blood cells.
Several therapies have been used including topical and systemic corticosteroids, vitamin C and topical and systemic anti-inflammatory agents. As aminaphtone has been used to treat patients with changes in capillary permeability and fragility[5, 6], it may be useful in the control of Schamberg's disease. The aim of this case report is to describe the treatment of Schamberg's disease using aminaphtone.
The current report describes the control of purpuric lesions using aminaphtone for a young female patient with Schamberg's disease. The etiology of this disease remains relatively unknown and there is no consensus to which medication is best for its control, perhaps due to the scarcity of published case reports.
The use of aminaphtone in this disease aims at improving capillary fragility and, in this case it successfully controlled the purpuric lesions. The use of other medications, such as pentoxifylline, corticoid and vitamin C, has also been described. This new option seems to be attractive due to the few side effects reported for the medication and the long periods without the reappearance of the purpuric lesions. However further studies are necessary to evaluate its efficacy over the long term.
The authors certifies that his institution has approved the protocol (n°0059.0.000.140-09Brazil)for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research of University Medical School of São Jose do Rio Preto-Brazil-FAMERP. The consent term was written and signed.
- Allevato M: Dermatosis purpúricas pigmentarias (Capilaritis). Act Terap Dermatol 2007, 30:222.
- Beauman JG: An unusual petechial rash. Am Fam Physician 2004,70(11):2197–8.PubMed
- Aiba S, Tagami H: Immunohistologic studies in Schamberg's disease. Evidence for cellular immune reaction in lesional skin. Arch Dermatol 1988, 124:1058–62.View ArticlePubMed
- Majid RM: Treatment of Schamberg's disease with pentoxifylline – therapeutic Trial. Journal of Pakistan Association of Dermatologists 2008, 18:97–99.
- Pereira de Godoy JM: Aminaphtone in idiopathic cyclic oedema syndrome. Phlebology 2008,23(3):118–9.View ArticlePubMed
- Godoy JMP, Batigália F, Mendes RN, Paiva JV, Oliveira JD: Aminaftona no tratamento da epistaxe. Rev bras hematol hemoter 2003,25(1):65–71.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.